Zhejiang Huahai Pharmaceutical Stock Forum

Zhejiang Huahai Pharmaceutical's share price drop doesn't align with its EPS growth and revenue increase, hinting at other influencing factors. Last year's performance suggests unresolved issues, and long-term share price weakness could be a negative sign or a potential turnaround for contrarian investors.

Analysts are more bearish on Zhejiang Huahai Pharmaceutical's future, reducing revenue and EPS estimates. The downgrade, coupled with high debt, hints at a potential business downturn.

Investors are hesitant to pay more for Zhejiang Huahai Pharmaceutical's stock due to expected limited future growth. The current P/E ratio mirrors these assumptions.

Zhejiang Huahai Pharmaceutical's efficient reinvestment has driven substantial earnings growth. Market fluctuations notwithstanding, the company's management has successfully utilized capital, as evidenced by its higher-than-average ROE.